Our Clinical Trials
Major Depressive Disorder (MDD)
Clinical trial researching a new adjunctive investigational treatment for MDD (AMPLIFY)
Drug: ABX-002
Age: 18-65
Phase: 2
Bipolar Depression
Clinical trial researching a new adjunctive investigational treatment for bipolar depression (AMPLIFY-BD)
Drug: ABX-002
Age: 18-65
Phase: 2
About Clinical Trials
A clinical trial is a research study that tests new medical approaches to detect, prevent, or treat diseases in people. Studying new treatments that may potentially improve people’s health involves rigorous evaluation in clinical trials to test whether a new treatment is safe and effective before it becomes available to large populations of patients.
Being part of a clinical trial has the potential to not only improve the lives of participants, but the lives of others as well. At Autobahn, we encourage potential participants to educate themselves about clinical trials and speak with their healthcare providers and loved ones to see if they might be a good fit for a study.
Frequently Asked Questions
Clinical trials are available to all patients who are interested in being a part of advancing the research of new treatments. Participation in a clinical trial is entirely voluntary and should be discussed in detail with a healthcare professional to assess whether you may be eligible and suitable for a clinical study.
If you are considering participating in a clinical trial, it is natural to have questions about how studies are run and the requirements for participants.
About Autobahn Therapeutics
Autobahn Therapeutics is a biotechnology company advancing innovative treatments for neuropsychiatric disorders through our clinical research programs. Our mission is to improve life health for people affected by CNS disorders by driving the regenerative power of the human body. Through collaboration with clinical experts, patient advocacy organizations, and disease communities, we are taking a patient- and caregiver-centric approach to the development of our product candidates.
Our current trials focus on ABX-002, our lead investigational treatment. ABX-002 is an orally administered, potent and selective thyroid hormone beta receptor (TRβ) agonist designed to potentially enhance the CNS benefits of thyroid hormone biology while also aiming to reduce the peripheral liabilities of synthetic thyroid hormone (e.g., triiodothyronine, T3), an unapproved treatment which has shown clinical benefit in numerous placebo-controlled human studies across MDD and bipolar depression.
We invite you to join us in our mission to restore hope for people affected by CNS disorders by learning more about our clinical trials.
